WASHINGTON (dpa-AFX) - Shares of Aevi Genomic Medicine Inc. (GNMX) got
pounded on Monday after it announced that the phase 2/3 efficacy study of
AEVI-001 in adolescent patients with ADHD (attention-deficit/hyperactivity
disorder) who have genetic...
The Vetr crowd upgraded their ratingforJazz Pharmaceuticals plc (NASDAQ: JAZZ) on Thursday, from 3 stars (Hold), issued two days ago, to 4 stars (Buy). At the time of the upgrade, crowd sentiment for the stock was mostly positive, with 83 percent...
JERUSALEM (dpa-AFX) - Alcobra Ltd.'s (ADHD) second phase III clinical trial
of its investigational product Metadoxine Extended Release for the treatment of
attention deficit hyperactivity disorder in adult patients has failed to meet
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.